Esperion Therapeutics Inc. [NASDAQ: ESPR] plunged by -$0.01 during the normal trading session on while it closed the day at $1.70.
Esperion Therapeutics Inc. stock has also loss -3.41% of its value over the past 7 days. However, ESPR stock has declined by -21.66% in the 3 months of the year. Over the past six months meanwhile, it has lost -33.85% and lost -43.14% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for ESPR stock reached $333.57 million, with 196.22 million shares outstanding and 194.07 million shares in the current float. Compared to the average trading volume of 6.98M shares, ESPR reached a trading volume of 3233822 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Esperion Therapeutics Inc. [ESPR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $7.59 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 1.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on June 20, 2024. The new note on the price target was released on January 03, 2024, representing the official price target for Esperion Therapeutics Inc. stock.
The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.13, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 1.20.
ESPR stock trade performance evaluation
Esperion Therapeutics Inc. [ESPR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.41. With this latest performance, ESPR shares dropped by -26.72% in over the last four-week period, additionally sinking by -33.85% over the last 6 months – not to mention a rise of 7.59% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 32.54, with the RSI for the last a single of trading hit 29.54, and the three-weeks RSI is set at 35.89 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 2.1886, while it was recorded at 1.7300 for the last single week of trading, and 2.2195 for the last 200 days.
Esperion Therapeutics Inc. [ESPR]: An insightful look at the core fundamentals
Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.49 and a Current Ratio set at 1.97.
Earnings per share (EPS) analysis for Esperion Therapeutics Inc. [ESPR] stock
With the latest financial reports released by the company, Esperion Therapeutics Inc. posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.43/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.
Esperion Therapeutics Inc. [ESPR]: Institutional Ownership
There are presently around $70.52%, or 70.88%% of ESPR stock, in the hands of institutional investors. The top three institutional holders of ESPR stocks are: WASATCH ADVISORS LP with ownership of 16.86 million shares, which is approximately 9.9628%. BLACKROCK INC., holding 13.98 million shares of the stock with an approximate value of $$31.04 million in ESPR stocks shares; and BLACKROCK INC., currently with $$24.01 million in ESPR stock with ownership which is approximately 6.3907%.
